Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P25189: Variant p.Ile62Phe

Myelin protein P0
Gene: MPZ
Feedback?
Variant information Variant position: help 62 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Isoleucine (I) to Phenylalanine (F) at position 62 (I62F, p.Ile62Phe). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and hydrophobic (I) to large size and aromatic (F) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 0 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In CMT1B. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 62 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 248 The length of the canonical sequence.
Location on the sequence: help VGSRVTLHCSFWSSEWVSDD I SFTWRYQPEGGRDAISIFHY The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         VGSRVTLHCSFWSSEWVSDDISFTWRYQPEGGRDAISIFHY

Mouse                         VGSQVTLHCSFWSSEWVSDDISFTWRYQPEGGRDAISIFHY

Rat                           VGSQVTLHCSFWSSEWVSDDISFTWRYQPEGGRDAISIFHY

Bovine                        VGSQVTLYCSFWSSEWVSDDLSFTWRYQPEGGRDAISIFHY

Horse                         VGSRVTLHCSFWSSEWVSDDISFTWRYQPEGGRDAISIFHY

Chicken                       VGSHVTLSCSFWSSEWISEDISYTWHFQAEGSRDSISIFHY

Xenopus laevis                AGSRVTLSCSFWSSEWISDDISVTWHYQPDHSREMYSIVHF

Xenopus tropicalis            VGSRVTLSCSFWSSEWISDDVSVTWHYQPDHSREMYSIFHY
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 30 – 248 Myelin protein P0
Topological domain 30 – 153 Extracellular
Domain 30 – 143 Ig-like V-type
Disulfide bond 50 – 127



Literature citations
A novel MPZ gene mutation in dominantly inherited neuropathy with focally folded myelin sheaths.
Nakagawa M.; Suehara M.; Saito A.; Takashima H.; Umehara F.; Saito M.; Kanzato N.; Matsuzaki T.; Takenaga S.; Sakoda S.; Izumo S.; Osame M.;
Neurology 52:1271-1275(1999)
Cited for: VARIANT CMT1B PHE-62; Demyelinating and axonal features of Charcot-Marie-Tooth disease with mutations of myelin-related proteins (PMP22, MPZ and Cx32): a clinicopathological study of 205 Japanese patients.
Hattori N.; Yamamoto M.; Yoshihara T.; Koike H.; Nakagawa M.; Yoshikawa H.; Ohnishi A.; Hayasaka K.; Onodera O.; Baba M.; Yasuda H.; Saito T.; Nakashima K.; Kira J.; Kaji R.; Oka N.; Sobue G.;
Brain 126:134-151(2003)
Cited for: VARIANTS CMT1B TYR-35; PHE-62; SER-63 DEL; CYS-68; GLU-93; CYS-98 AND PHE-146; VARIANTS CMT2I VAL-75; ARG-81; MET-124; ARG-130 AND ARG-167;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.